Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:ATHX's Cash to Debt is ranked higher than
87% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. NAS:ATHX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:ATHX' s Cash to Debt Range Over the Past 10 Years
Min: 0.12  Med: N/A Max: No Debt
Current: No Debt
Equity to Asset 0.69
NAS:ATHX's Equity to Asset is ranked higher than
52% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:ATHX: 0.69 )
Ranked among companies with meaningful Equity to Asset only.
NAS:ATHX' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.68 Max: 0.93
Current: 0.69
0.19
0.93
Interest Coverage No Debt
NAS:ATHX's Interest Coverage is ranked higher than
83% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ATHX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ATHX' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
F-Score: 4
Z-Score: -6.84
M-Score: 12.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -12.34
NAS:ATHX's Operating margin (%) is ranked higher than
65% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. NAS:ATHX: -12.34 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:ATHX' s Operating margin (%) Range Over the Past 10 Years
Min: -1787.55  Med: -440.21 Max: -12.34
Current: -12.34
-1787.55
-12.34
Net-margin (%) -17.12
NAS:ATHX's Net-margin (%) is ranked higher than
63% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. NAS:ATHX: -17.12 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:ATHX' s Net-margin (%) Range Over the Past 10 Years
Min: -1360.57  Med: -431.54 Max: -17.12
Current: -17.12
-1360.57
-17.12
ROE (%) -23.94
NAS:ATHX's ROE (%) is ranked higher than
58% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. NAS:ATHX: -23.94 )
Ranked among companies with meaningful ROE (%) only.
NAS:ATHX' s ROE (%) Range Over the Past 10 Years
Min: -176.55  Med: -106.99 Max: -23.94
Current: -23.94
-176.55
-23.94
ROA (%) -16.50
NAS:ATHX's ROA (%) is ranked higher than
61% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. NAS:ATHX: -16.50 )
Ranked among companies with meaningful ROA (%) only.
NAS:ATHX' s ROA (%) Range Over the Past 10 Years
Min: -495.2  Med: -67.53 Max: -16.5
Current: -16.5
-495.2
-16.5
ROC (Joel Greenblatt) (%) -203.36
NAS:ATHX's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NAS:ATHX: -203.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:ATHX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4646.21  Med: -1938.41 Max: -203.36
Current: -203.36
-4646.21
-203.36
Revenue Growth (3Y)(%) -18.60
NAS:ATHX's Revenue Growth (3Y)(%) is ranked lower than
73% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:ATHX: -18.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:ATHX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -37 Max: 39.5
Current: -18.6
0
39.5
EBITDA Growth (3Y)(%) -24.90
NAS:ATHX's EBITDA Growth (3Y)(%) is ranked lower than
78% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:ATHX: -24.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:ATHX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -28.65 Max: -10.7
Current: -24.9
EPS Growth (3Y)(%) -23.70
NAS:ATHX's EPS Growth (3Y)(%) is ranked lower than
74% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:ATHX: -23.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:ATHX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -27.65 Max: -4.1
Current: -23.7
GuruFocus has detected 2 Warning Signs with Athersys Inc $NAS:ATHX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ATHX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

ATHX Guru Trades in Q4 2015

Jim Simons 112,834 sh (New)
» More
Q1 2016

ATHX Guru Trades in Q1 2016

Jim Simons 343,034 sh (+204.02%)
» More
Q2 2016

ATHX Guru Trades in Q2 2016

Joel Greenblatt 10,296 sh (New)
Jim Simons 246,534 sh (-28.13%)
» More
Q3 2016

ATHX Guru Trades in Q3 2016

Joel Greenblatt Sold Out
Jim Simons 136,834 sh (-44.50%)
» More
» Details

Insider Trades

Latest Guru Trades with ATHX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ADVM, NAS:RGLS, NAS:VVUS, NAS:ALBO, NAS:VBIV, NAS:CNAT, NAS:EGLT, NAS:GNCA, NAS:KIN, NAS:EVGN, OTCPK:MTNB, NAS:AUPH, NAS:MRTX, NAS:KURA, NAS:GLYC, OTCPK:RNUGF, NAS:MDWD, OTCPK:HPPI, NAS:REPH, NAS:ARWR » details
Traded in other countries:4LS.Germany,
Athersys Inc is a biopharmaceutical company developing regenerative medicine. It is engaged in the discovery and development of therapies designed to extend and enhance human life.

Athersys Inc was incorporated in Delaware on October 24, 1995. On June 8, 2007, it merged with a wholly owned subsidiary of BTHC VI, Inc., a Delaware corporation, and, on August 31, 2007, BTHC VI, Inc. changed its name to Athersys, Inc. It is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates. The Companys current product development portfolio consists of MultiStem, a patented and proprietary stem cell product that it is developing as a treatment for multiple disease indications, and that is currently being evaluated in two ongoing clinical trials. In addition, it is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. Its business objective is to discover, develop and commercialize novel therapeutic products for disease indications that represent areas of clinical need and commercial opportunity. Its partner, Pfizer Inc. is conducting Phase 2 clinical study of MultiStem cells. Myocardial infarction is one of the causes of death and disability in the United States. The Company is engaged in five programs including, Inflammatory Bowel Disease; Ischemic Stroke; Acute Myocardial Infarction; Hematopoietic Stem Cell Transplant / GvHD; Multistem. The Company partners with Pfizer, RTI, Angiotech and Bristol-Myers Squibb. It competes with Stem Cells Inc., Johnson & Johnson, Celgene Corporation, or Celgene, Advanced Cell Technology, Inc. The Company has 36 issued patents; 16 United States and 20 international. The Company and its related programs and the products are subject to government regulations.

Ratios

vs
industry
vs
history
P/B 7.70
ATHX's P/B is ranked lower than
80% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.62 vs. ATHX: 7.70 )
Ranked among companies with meaningful P/B only.
ATHX' s P/B Range Over the Past 10 Years
Min: 0.18  Med: 4.66 Max: 23.38
Current: 7.7
0.18
23.38
P/S 4.46
ATHX's P/S is ranked higher than
72% of the 682 Companies
in the Global Biotechnology industry.

( Industry Median: 10.89 vs. ATHX: 4.46 )
Ranked among companies with meaningful P/S only.
ATHX' s P/S Range Over the Past 10 Years
Min: 1.15  Med: 7.64 Max: 152.38
Current: 4.46
1.15
152.38
EV-to-EBIT -31.19
ATHX's EV-to-EBIT is ranked lower than
99.99% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 20.60 vs. ATHX: -31.19 )
Ranked among companies with meaningful EV-to-EBIT only.
ATHX' s EV-to-EBIT Range Over the Past 10 Years
Min: -53.3  Med: -2.6 Max: 3
Current: -31.19
-53.3
3
EV-to-EBITDA -34.45
ATHX's EV-to-EBITDA is ranked lower than
99.99% of the 264 Companies
in the Global Biotechnology industry.

( Industry Median: 17.09 vs. ATHX: -34.45 )
Ranked among companies with meaningful EV-to-EBITDA only.
ATHX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -57.6  Med: -2.7 Max: 3.1
Current: -34.45
-57.6
3.1
Current Ratio 3.98
ATHX's Current Ratio is ranked lower than
51% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ATHX: 3.98 )
Ranked among companies with meaningful Current Ratio only.
ATHX' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 4.47 Max: 12.58
Current: 3.98
0.47
12.58
Quick Ratio 3.98
ATHX's Quick Ratio is ranked higher than
51% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. ATHX: 3.98 )
Ranked among companies with meaningful Quick Ratio only.
ATHX' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 4.47 Max: 12.58
Current: 3.98
0.47
12.58
Days Sales Outstanding 4.03
ATHX's Days Sales Outstanding is ranked higher than
93% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 62.07 vs. ATHX: 4.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATHX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.03  Med: 68.68 Max: 156.08
Current: 4.03
11.03
156.08

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.40
ATHX's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. ATHX: -16.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATHX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -298.1  Med: -43.95 Max: 0
Current: -16.4
-298.1
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.28
ATHX's Price/Net Cash is ranked lower than
69% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.31 vs. ATHX: 10.28 )
Ranked among companies with meaningful Price/Net Cash only.
ATHX' s Price/Net Cash Range Over the Past 10 Years
Min: 0.33  Med: 6.56 Max: 23
Current: 10.28
0.33
23
Price/Net Current Asset Value 9.60
ATHX's Price/Net Current Asset Value is ranked lower than
69% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. ATHX: 9.60 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ATHX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.32  Med: 6.09 Max: 69.5
Current: 9.6
0.32
69.5
Price/Tangible Book 7.70
ATHX's Price/Tangible Book is ranked lower than
72% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. ATHX: 7.70 )
Ranked among companies with meaningful Price/Tangible Book only.
ATHX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.27  Med: 4.6 Max: 21.38
Current: 7.7
0.27
21.38
Price/Median PS Value 0.58
ATHX's Price/Median PS Value is ranked higher than
76% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ATHX: 0.58 )
Ranked among companies with meaningful Price/Median PS Value only.
ATHX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 0.97 Max: 18
Current: 0.58
0.2
18
Earnings Yield (Greenblatt) (%) -3.20
ATHX's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. ATHX: -3.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ATHX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 32.8  Med: 206.2 Max: 17247.5
Current: -3.2
32.8
17247.5

More Statistics

Revenue (TTM) (Mil) $26.97
EPS (TTM) $ -0.05
Beta-0.94
Short Percentage of Float10.52%
52-Week Range $1.03 - 2.90
Shares Outstanding (Mil)85.50

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 17 9 1 159
EPS ($) -0.19 -0.33 -0.21 0.74
EPS w/o NRI ($) -0.19 -0.33 -0.21 0.74
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ATHX

Headlines

Articles On GuruFocus.com
Athersys Inc. (ATHX) CEO Bokkelen Gil Van buys 10,000 Shares Mar 18 2009 

More From Other Websites
Athersys Subsidiary and Leading Animal Health Company Enter Into Research and Option Agreement for... Jan 18 2017
ATHERSYS, INC / NEW Files SEC form 8-K, Change in Directors or Principal Officers Jan 13 2017
ETFs with exposure to Athersys, Inc. : December 29, 2016 Dec 29 2016
Ironwood, Allergan Report Positive Linzess IBS-C Study Data Dec 23 2016
Alexion Soliris Fails in Phase II/III Delayed Graft Function Study Dec 22 2016
Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy Dec 21 2016
Celgene (CELG) Otezla Approved in Japan for Two Indications Dec 21 2016
How Iradimed Corp (IRMD) Stacks Up Against Its Peers Dec 15 2016
ETFs with exposure to Athersys, Inc. : December 13, 2016 Dec 13 2016
Emergent BioSolutions (EBS) in Focus: Stock Rises 18.9% Dec 12 2016
ETFs with exposure to Athersys, Inc. : November 29, 2016 Nov 29 2016
Epizyme Tazemetostat Gets Fast Track Designation in U.S. Nov 29 2016
Athersys, Inc. :ATHX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 Nov 28 2016
Navidea Inks Deal to to Sell Lymphoseek to Cardinal Health Nov 25 2016
ATHERSYS, INC / NEW Financials Nov 17 2016
New Strong Buy Stocks for November 14th Nov 14 2016
Athersys 3Q Loss $6M or 7 Cents a Share (ATHX) Nov 10 2016
Edited Transcript of ATHX earnings conference call or presentation 9-Nov-16 9:30pm GMT Nov 09 2016
Athersys Reports Third Quarter 2016 Results Nov 09 2016
ATHERSYS, INC / NEW Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)